-

Stevanato Group to Participate in Upcoming Investor Conferences

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in two upcoming investor conferences.

  • Monday, November 17, 2025, at 8:40 a.m. ET - The 7th Annual Wolfe Research Healthcare Conference in New York City
  • Wednesday, November 19, 2025, at 11:00 a.m. GMT - The Jefferies Global Healthcare Conference in London

A live webcast of each event will be available on the Company’s website at www.stevanatogroup.com under the "Investors" section. Replays will remain available for approximately 90 days after each event.

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical, and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value-added solutions to clients.

For more information, please visit: www.stevanatogroup.com.

Contacts

Investor Relations
Lisa Miles
lisa.miles@stevanatogroup.com
Giacomo Guiducci
giacomo.guiducci@stevanatogroup.com

Media
Caterina Tripepi
caterina.tripepi@stevanatogroup.com

Stevanato Group S.p.A.

NYSE:STVN

Release Versions

Contacts

Investor Relations
Lisa Miles
lisa.miles@stevanatogroup.com
Giacomo Guiducci
giacomo.guiducci@stevanatogroup.com

Media
Caterina Tripepi
caterina.tripepi@stevanatogroup.com

More News From Stevanato Group S.p.A.

Stevanato Group to Participate in Upcoming Investor Conferences

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences. The Company will participate in the Jefferies Global Healthcare Conference taking place from Monday, November 16, 2026, to Thursday, November 19, 2026, in London. The Company will host a...

Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2026. Third Quarter of 2026 Highlights (comparisons to prior-year period) Revenue increased 8% to €326.1 million, and on an organic basis* revenue increased 8%. Revenue from high-value solutions represente...

Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with Aptar Pharma to provide system-level data supporting earlier evaluation of pre-filled syringe configurations for biotech and pharmaceutical companies, with a focus on sensitive biologics and other injectable therapie...
Back to Newsroom